Immunocore (NASDAQ:IMCR) Announces Quarterly Earnings Results

Immunocore (NASDAQ:IMCR) released its earnings results on Wednesday. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.16), Zacks reports. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%.

Immunocore Price Performance

Shares of IMCR traded up $1.78 during mid-day trading on Wednesday, hitting $30.99. 96,158 shares of the company traded hands, compared to its average volume of 217,701. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -32.62 and a beta of 0.77. Immunocore has a one year low of $27.69 and a one year high of $72.56. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The business has a 50-day moving average of $29.98 and a 200 day moving average of $31.97.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IMCR. Mizuho lowered Immunocore from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $72.00 to $38.00 in a research note on Monday, November 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price target on shares of Immunocore in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Monday, January 27th. Finally, Morgan Stanley restated an “equal weight” rating and set a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.